Get the Stockscreener App
21.73
0.64%
-0.14
After Hours:
21.77
0.04
+0.18%
Arrivent Biopharma Inc stock is traded at $21.73, with a volume of 106.49K.
It is down -0.64% in the last 24 hours and down -19.25% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$21.87
Open:
$22.11
24h Volume:
106.49K
Relative Volume:
0.71
Market Cap:
$739.17M
Revenue:
-
Net Income/Loss:
$-81.05M
P/E Ratio:
-8.2838
EPS:
-2.6232
Net Cash Flow:
$-68.97M
1W Performance:
-1.36%
1M Performance:
-19.25%
6M Performance:
-20.37%
1Y Performance:
+10.81%
1-Day Range:
$21.40
$22.16
1-Week Range:
$21.34
$22.92
52-Week Range:
$14.35
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
21.73 | 739.17M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.01 | 128.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.83 | 81.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
571.00 | 34.69B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
233.07 | 30.17B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
242.66 | 26.02B | 3.32B | -860.46M | -1.04B | -8.32 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-25 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Oppenheimer | Outperform |
| Apr-30-24 | Initiated | H.C. Wainwright | Buy |
| Feb-20-24 | Initiated | Citigroup | Buy |
| Feb-20-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
ArriVent BioPharma (NASDAQ:AVBP) Now Covered by Analysts at Guggenheim - Defense World
Guggenheim starts ArriVent Biopharma with a Buy on firmonertinib potential - TipRanks
ArriVent BioPharma (NASDAQ:AVBP) Earns “Buy” Rating from HC Wainwright - Defense World
Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength - MSN
H.C. Wainwright maintains Buy on ArriVent shares, $39 target By Investing.com - Investing.com Canada
ArriVent BioPharma Reports 2024 Financial Results and Key Achievements - MSN
H.C. Wainwright maintains Buy on ArriVent shares, $39 target - Investing.com India
Rhumbline Advisers Purchases 3,069 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
FY2025 EPS Estimates for AVBP Reduced by Lifesci Capital - Defense World
New York State Common Retirement Fund Boosts Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma Reports 2024 Financial Results and Progress - MSN
(AVBP) Investment Report - Stock Traders Daily
Lepu Biopharma Co., Ltd. Announces Update on New Drug Application of MRG003 -March 03, 2025 - Marketscreener.com
ArriVent BioPharma, Inc. SEC 10-K Report - TradingView
ArriVent BioPharma Reports Full Year 2024 Financial Results - The Manila Times
IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip
Where are the Opportunities in (AVBP) - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Update - MarketBeat
Mirae Asset Global Investments Co. Ltd. Makes New Investment in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Mirae Asset Global Investments Co. Ltd. Purchases Shares of 1,123 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Armenian Reporter
How To Trade (AVBP) - Stock Traders Daily
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Expands By 13.1% - MarketBeat
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - News & Insights
Asia’s NewCo Model, FDA tipping point, Vertex’s pain drug: a BioCentury podcast - BioCentury
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Bought by JPMorgan Chase & Co. - Defense World
(AVBP) Trading Signals - Stock Traders Daily
The NewCo boom signals China’s galloping speed of innovation - BioCentury
Abbvie seeks molecular glue degraders from Neomorph - BioCentury
ArriVent in Newtown Square Sees Big Potential in New Cancer Drug - DELCO.Today
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN
IPO excitement heats up as Metsera targets $1.8B valuation, Aurion joins queue - FirstWord Pharma
Equities Analysts Set Expectations for AVBP Q1 Earnings - Defense World
HC Wainwright Issues Positive Estimate for AVBP Earnings - MarketBeat
More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal - BioWorld Online
ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright - Yahoo Finance
ArriVent Biopharma enters license agreement with Lepu Biopharma - MSN
Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim - MedCity News
Intellia makes progress on HAE study; 2 more China drug deals - BioPharma Dive
ArriVent inks ADC licensing deal with Lepu Biopharma - The Pharma Letter
ArriVent bets big on experimental cancer drug with potential $1B licensing deal - The Business Journals
Arrivent Biopharma licenses ex-China rights to Lepu’s ADC for gastrointestinal cancers - BioWorld Online
ArriVent Joins Chinese Licensing Trend With Potential $1.2B+ ADC Deal with Lepu - BioSpace
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers - The Manila Times
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the - Digital More
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers - The Manila Times
Lepu Biopharma Co., Ltd. Enters into an Exclusive Licensing Agreement with Arrivent Biopharma, Inc - Marketscreener.com
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma - WICZ
Lepu Biopharma Grants Exclusive License for Novel ADC MRG007 to ArriVent - TipRanks
ArriVent BioPharma Secures Global Rights to Promising Cancer Drug MRG007 in $1.2B Deal - StockTitan
(AVBP) Investment Analysis - Stock Traders Daily
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):